NEXI (NexImmune) Debt-to-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexImmune Debt-to-Asset?

NexImmune's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. NexImmune's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. NexImmune's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $5.86 Mil. NexImmune's debt to asset for the quarter that ended in Jun. 2024 was 0.00.

NexImmune Debt-to-Asset Historical Data

The historical data trend for NexImmune's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Debt-to-Asset Chart

NexImmune Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

1.69

0.02

0.01

NexImmune Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.04	0.01	-	-

Competitive Comparison of NexImmune's Debt-to-Asset

For the Biotechnology subindustry, NexImmune's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexImmune's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NexImmune's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NexImmune's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

NexImmune Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NexImmune's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.069	+	0)	/	8.594
	=	0.01

NexImmune's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	5.861
	=	0.00

NexImmune (OTCPK:NEXI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NexImmune Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NexImmune's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NexImmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (OTCPK:NEXI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

9119 Gaither Road, Gaithersburg, MD, USA, 20877

Website

https://www.neximmune.com

NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Executives

Alan S. Roemer	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover	officer: VP, Corporate Controller	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao	director	10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi	director	C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke	officer: Chief Science Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones	officer: Chief Operating Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis	officer: EVP of R&D	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer	director, officer: President and CEO	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer	officer: Chief Financial Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight	officer: Chief Medical Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877